false 0001840425 0001840425 2026-08-07 2026-08-07 0001840425 OSRH:CommonStockParValue0.0001PerShareMember 2026-08-07 2026-08-07 0001840425 OSRH:RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember 2026-08-07 2026-08-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 7, 2026

 

OSR HEALTH, INC.

(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-41390   84-5052822
(State or Other Jurisdiction   (Commission File Number)   (IRS Employer
of Incorporation)       Identification No.)

 

10900 NE 4th Street, Suite 2300, Bellevue, WA   98004
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code (425) 635-7700

 

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, par value $0.0001 per share   OSRH   The Nasdaq Stock Market LLC
Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share   OSRHW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders

 

On August 7, 2026, the Company held an annual meeting of its stockholders (the “Annual Meeting”). As of the close of business on July 8, 2026, the record date for the Annual Meeting, there were 35,118,692 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), issued and outstanding, each of which was entitled to one vote with respect to each of the proposals presented at the Annual Meeting. A total of 21,088,120 shares of Common Stock, representing approximately 60.05% of the outstanding shares of Common Stock entitled to vote at the Annual Meeting, were present in person or by proxy, constituting a quorum. The proposals listed below are described in more detail in the Definitive Proxy Statement on Form DEF 14A filed by the Company with the SEC on July 16, 2026 (the “Proxy Statement”).

 

Director Proposal

 

At the Annual Meeting, stockholders re-elected seven (7) directors to serve until the 2027 Annual Meeting of Stockholders or until their successors are duly elected and qualified. The final voting results were as follows:

 

    FOR   WITHHELD   RESULT
Kuk Hyoun Hwang   15,174,735   129,046   Elected
Jun Chul Whang   15,175,735   128,046   Elected
Alcide Barberis   15,185,385   118,396   Elected
Seng Chin Mah   15,170,280   133,501   Elected
Hyuk Joo Jee   15,174,735   129,046   Elected
Joong Myung Cho   15,170,315   133,466   Elected
Reto Fierz   15,179,965   123,816   Elected

 

Ratification of Independent Auditor Proposal

 

The stockholders approved the Ratification of Independent Auditor Proposal by the votes set forth in the table below:

 

FOR   AGAINST   ABSTAIN
20,296,535   201,444   590,141

 

Executive Compensation Proposal

 

The stockholders approved the Executive Compensation Proposal by the votes set forth in the table below:

 

FOR   AGAINST   ABSTAIN
15,059,135   83,113   161,533

 

Authorized Shares Increase Proposal

 

The stockholders approved the Authorized Shares Increase Proposal by the votes set forth in the table below:

 

FOR   AGAINST   ABSTAIN
19,922,498   581,009   584,613

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: August 10, 2026

 

  OSR HEALTH, INC.
       
  By:  /s/ Kuk Hyoun Hwang
    Name:  Kuk Hyoun Hwang
    Title: Chief Executive Officer

 

2

 


ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

XBRL SCHEMA FILE

XBRL DEFINITION FILE

XBRL LABEL FILE

XBRL PRESENTATION FILE

IDEA: R1.htm

IDEA: FilingSummary.xml

IDEA: MetaLinks.json

IDEA: ea0301344-8k_osrhealth_htm.xml